1
|
Abstract
Alcoholic hepatitis is the severest clinical presentation of alcoholic liver disease. Lacking an effective pharmacologic treatment, alcoholic hepatitis is associated with a poor prognosis and its recovery relies mostly on abstinence. With alcohol use disorder being universally on the rise, the impact of alcoholic hepatitis on society and health-care costs is expected to increase significantly. Prognostic factors and liver biopsy can help with timely diagnosis, to determine eligibility and response to corticosteroids, and for prognostication and transplant referral. Although recent discoveries in the pathophysiology of alcoholic hepatitis are encouraging and could pave the way for novel treatment modalities, a multidisciplinary approach considering timely identification and treatment of liver-related complications, infectious and metabolic disease, malnutrition, and addiction counseling should be emphasized. Apart from proper selection of candidates, transplant programs should provide adequate post-transplant addiction support in order to make of early liver transplantation for alcoholic hepatitis the ultimate sobering experience in the next decade.
Collapse
Affiliation(s)
- Vikrant Rachakonda
- Division of Gastroenterology and Hepatology, Starzl Transplantation Institute, and Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Ramon Bataller
- Division of Gastroenterology and Hepatology, Starzl Transplantation Institute, and Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| | - Andres Duarte-Rojo
- Division of Gastroenterology and Hepatology, Starzl Transplantation Institute, and Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, PA, 15213, USA
| |
Collapse
|
2
|
Li D, Zhao H, Gelernter J. Strong protective effect of the aldehyde dehydrogenase gene (ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. Hum Genet 2012; 131:725-37. [PMID: 22102315 PMCID: PMC3548401 DOI: 10.1007/s00439-011-1116-4] [Citation(s) in RCA: 84] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2011] [Accepted: 11/12/2011] [Indexed: 12/20/2022]
Abstract
Alcohol is oxidized to acetaldehyde, which in turn is oxidized to acetate. The aldehyde dehydrogenase 2 gene (ALDH2) is the most important gene responsible for acetaldehyde metabolism. Individuals heterozygous or homozygous for the lys (A or *2) allele at the single nucleotide polymorphism (SNP) glu504lys (rs671) of ALDH2 have greatly reduced ability to metabolize acetaldehyde, which greatly decreases their risk for alcohol dependence (AD). Case-control studies have shown association between this SNP and alcohol dependence as well as alcohol-induced liver disease. However, some studies have produced insignificant results. Using cumulative data from the past 20 years predominately from Asian populations (from both English and Chinese publications), this meta-analysis sought to examine and update whether the aggregate data provide new evidence of statistical significance for the proposed association. Our results (9,678 cases and 7,331 controls from 53 studies) support a strong association of alcohol abuse and dependence, with allelic P value of 3 × 10(-56) and OR of 0.23 (0.2, 0.28) under the random effects model. The dominant model (lys-lys + lys-glu vs. glu-glu) also showed strong association with P value of 1 × 10(-44) and OR of 0.22 (0.18, 0.27). When stricter criteria and various sub-group analyses were applied, the association remained strong (for example, OR = 0.23 (0.18, 0.3) and P = 2 × 10(-28) for the alcoholic patients with alcoholic liver disease, cirrhosis, or pancreatitis). These findings provide confirmation of the involvement of the human ALDH2 gene in the pathogenesis of AD as well as alcohol-induced medical illnesses in East-Asians.
Collapse
Affiliation(s)
- Dawei Li
- Department of Psychiatry, School of Medicine, Yale University, New Haven, CT 06511, USA.
| | | | | |
Collapse
|
4
|
Alcohol and Cancer Epidemiology. ALCOHOL AND CANCER 2011. [PMCID: PMC7122198 DOI: 10.1007/978-1-4614-0040-0_3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
In a comprehensive worldwide assessment of cancer risk related to food and nutrition, the American Institute for Cancer Research (AICR 2007) identified alcohol consumption as a “convincing” or “probable” risk factor for esophageal, mouth, and laryngeal cancers, for liver cancer, for breast cancer in women, and for colorectal cancer especially in men. The World Health Organization’s Global Burden of Disease Project concluded that “A total of 390,000 cases of cancer are attributable to alcohol drinking worldwide, representing 3.6% of all cancers (5.2% in men, 1.7% in women)” each year, with a corresponding annual mortality rate of 233,000, representing 3.5% of all cancer deaths (Boffetta et al. 2006). For the USA, the Alcohol-Related Disease Impact (ARDI) report indicates an annual rate of 2,464 deaths in six different alcohol-related cancer categories for the period 2001–2006 (CDC 2010).
Collapse
|
5
|
Guo W, Wang Q, Lanzi G, Luobu O, Ma X, Wang Y, Zhen P, Ji Y, Wei G, Wang Z, Deng W, Zhuoma B, Shi X, Yan C, He C, Liu X, Wu Y, Luo H, Collier DA, Ball D, Li T, Hu X. Interaction among genes influencing ethanol metabolism and sex is association with alcohol use disorders in a Tibet population. Am J Med Genet B Neuropsychiatr Genet 2010; 153B:561-569. [PMID: 19655364 DOI: 10.1002/ajmg.b.31020] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Associations between alcohol use disorders and polymorphisms of genes influencing ethanol metabolism have been widely reported, but gene-gene and gene-sex interaction studies have rarely been examined. Using a set of samples collected during an epidemiological study of alcohol use disorders AUDs in a Tibetan population in China, we performed a case-control study to investigate the relationship between the functional polymorphisms of genes influencing ethanol metabolism and AUDs. The sample included 383 individuals with an AUDIT score >or=10 and 350 control subjects with the AUDIT score <or=5. All participants were genotyped for ALDH2*1/*2, ADH1B*1/*2, and CYP2E1*c1/c2*. Data were analyzed employing an integrated strategy using MDR, SPSS, and UNPHASED software. The MDR analysis showed that the four-factor model including ADH1B*1/*2, ALDH2*1/*2, and CYP2E1*c1/*c2 polymorphisms, and sex was the most accurate model associated with AUDs with the highest OR 3.299. It also revealed that CYP2E1 *c1/*c2 polymorphism interacted significantly with sex. Independent analysis confirmed that both ADH2*2 and ALDH2*2 allele were significantly associated with AUDs (OR: 0.441 for ADH2*2 and 0.137 for ALDH2*2). CYP2E1*c2 was positively associated with AUDs only in males homozygotic for ALDH2*1 and ADH1B*1 (OR: 2.585). Cumulative association analysis showed the number of protective alleles and genotypes were negatively associated with AUDs. In conclusion, ALDH2*2 and ADH1B*2 alleles were not only independently associated with AUDs but also demonstrated cumulative dosage effects. However the positive association between CYP2E1*c2 allele and AUDs might only exist in males homozygotic for ALDH2*1 and ADH1B*1.
Collapse
Affiliation(s)
- Wanjun Guo
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Qiang Wang
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Gongga Lanzi
- Medical School, University of Tibet, Lasha, Tibet, P.R. China
| | - Ouzhu Luobu
- Medical School, University of Tibet, Lasha, Tibet, P.R. China
| | - Xiaohong Ma
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Yingcheng Wang
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Puo Zhen
- Medical School, University of Tibet, Lasha, Tibet, P.R. China
| | - Yulin Ji
- Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Geng Wei
- Department of Mental Health, People's Hospital of Tibet Autonomous Region, Lasha, P.R. China
| | - Zheng Wang
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China.,Department of Science and Technology, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Wei Deng
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Basang Zhuoma
- Medical School, University of Tibet, Lasha, Tibet, P.R. China
| | - Xiaoming Shi
- Medical School, University of Tibet, Lasha, Tibet, P.R. China
| | - Chengyin Yan
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Chan He
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Xiehe Liu
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Yuejing Wu
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - Hongrong Luo
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China
| | - David A Collier
- Division of Psychological Medicine, Institute of Psychiatry, King's College, London, UK.,SGDP Centre, Institute of Psychiatry, King's College, London, UK
| | - David Ball
- SGDP Centre, Institute of Psychiatry, King's College, London, UK
| | - Tao Li
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China.,Division of Psychological Medicine, Institute of Psychiatry, King's College, London, UK.,SGDP Centre, Institute of Psychiatry, King's College, London, UK
| | - Xun Hu
- Psychiatric Laboratory, Department of Psychiatry, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, P.R. China.,Division of Psychological Medicine, Institute of Psychiatry, King's College, London, UK.,SGDP Centre, Institute of Psychiatry, King's College, London, UK
| |
Collapse
|